Comparison
Cagrilintide vs. Liraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
1415456-99-3
204656-20-2
Molecular weight
4253.7 g/mol
3751 g/mol
Half-life
168 h
13 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1